Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2025-02-28 00:00:00 ET · period of report 2025-02-26 · accession 0000950170-25-030052 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-28 | 2025-02-26 | ANTX | Day Lucy | CFO | A - Grant | $0.00 | +46.5K | 79.2K | +142% | $0 |
| D | 2025-02-28 | 2025-02-26 | ANTX | Day Lucy | CFO | A - Grant | $0.00 | -93.0K | 93.0K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-26 | A | A | 46,500 | $0.00 | 79,170 | D | — | — | (F1) Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date. (F2) Includes 20,625 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2025-02-26 | A | D | 93,000 | $0.00 | 93,000 | D | $1.13 · — to 2035-02-25 | 93,000 Common Stock | (F3) The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date. |